{"disease":{"id":"unknown","name":"unknown"},"drugs":{"marketed":[{"drug_id":"chembl-chembl2108611","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"INOTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":61,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate that binds to CD22 on tumor cells, internalizes, and releases a cytotoxic agent causing DNA damage and cell death."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"menc","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MenC","company_name":"Novartis Vaccines","drug_phase":"marketed","molecular_target":"Capsular polysaccharide of Neisseria meningitidis serogroup C","drug_class":"Conjugate vaccine","quality_score":46,"revenue":null,"mechanism":"MenC stimulates the immune system to produce antibodies against the capsular polysaccharide of Neisseria meningitidis serogroup C."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"loncastuximab-tesirine","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LONCASTUXIMAB TESIRINE","company_name":"","drug_phase":"marketed","molecular_target":"CD19","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":50,"revenue":null,"mechanism":"Loncastuximab tesirine is an ADC that targets CD19 on B-lineage cells, internalizes, and releases a cytotoxic agent to induce cell death."},{"drug_id":"cysteamine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CYSTEAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Cystine","drug_class":"Cystine-depleting agents","quality_score":44,"revenue":null,"mechanism":"Cysteamine depletes cystine by converting it to cysteine and cysteine-cysteamine mixed disulfides, reducing corneal cystine crystal accumulation."},{"drug_id":"sinecatechins","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SINECATECHINS","company_name":"","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Polyphenols","quality_score":46,"revenue":null,"mechanism":"The exact mechanism of action of sinecatechins in the treatment of genital and perianal warts is unknown, but it has demonstrated anti-oxidative activity in vitro."},{"drug_id":"therapeutic-entecavir","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Therapeutic entecavir","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"HBV DNA polymerase","drug_class":"Nucleoside analog reverse transcriptase inhibitor (NRTI)","quality_score":46,"revenue":null,"mechanism":"Entecavir is a guanosine nucleoside analog that selectively inhibits the replication of hepatitis B virus (HBV) DNA polymerase."},{"drug_id":"highly-active-antiretroviral-therapy-haart","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"highly active antiretroviral therapy (HAART)","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"HIV enzymes and processes","drug_class":"Antiretroviral","quality_score":42,"revenue":null,"mechanism":"HAART combines multiple antiretroviral drugs to inhibit different stages of the HIV life cycle, thereby reducing viral replication and improving immune function."},{"drug_id":"systane-balance","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Systane Balance","company_name":"Southern California College of Optometry at Marshall B. Ketchum University","drug_phase":"marketed","molecular_target":"Tear film stability","drug_class":"Lubricant eye drops","quality_score":39,"revenue":null,"mechanism":"Systane Balance is a lubricant eye drop that helps to relieve dryness and discomfort by replenishing the tear film."},{"drug_id":"prontogest-400-mg-vaginal-pessaries","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prontogest 400 mg vaginal pessaries","company_name":"Ain Shams Maternity Hospital","drug_phase":"marketed","molecular_target":"Uterine smooth muscle and cervical tissue","drug_class":"Progesterone","quality_score":42,"revenue":null,"mechanism":"Prontogest 400 mg vaginal pessaries work by delivering progesterone to the vaginal mucosa, which helps maintain uterine quiescence and prevent preterm labor."},{"drug_id":"almotriptan-malate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALMOTRIPTAN MALATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT1B/1D receptors","drug_class":"Triptan","quality_score":52,"revenue":null,"mechanism":"Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation."},{"drug_id":"almotriptan-malate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALMOTRIPTAN MALATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT1B/1D receptors","drug_class":"Triptan","quality_score":52,"revenue":null,"mechanism":"Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation."},{"drug_id":"suprep-bowel-prep-kit","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SUPREP Bowel Prep Kit","company_name":"Braintree Laboratories","drug_phase":"marketed","molecular_target":"Intestinal lumen","drug_class":"Osmotic laxative","quality_score":null,"revenue":null,"mechanism":"SUPREP works by drawing water into the intestines to flush out the contents, preparing the bowel for colonoscopy."},{"drug_id":"telotristat-etiprate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TELOTRISTAT ETIPRATE","company_name":"","drug_phase":"marketed","molecular_target":"Tryptophan Hydroxylase-1 (TPH1)","drug_class":"Serotonin Synthesis Inhibitor","quality_score":null,"revenue":null,"mechanism":"Telotristat etiprate inhibits tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis, thereby reducing serotonin levels in the body."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"flupentixole","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flupentixole","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"Dopamine D2 receptors","drug_class":"Antipsychotic","quality_score":null,"revenue":null,"mechanism":"Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain."},{"drug_id":"flupentixole","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flupentixole","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"Dopamine D2 receptors","drug_class":"Antipsychotic","quality_score":null,"revenue":null,"mechanism":"Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain."},{"drug_id":"salmeterol-50-mcg-via-diskus","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salmeterol 50 mcg via DISKUS","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Beta2-adrenergic receptors","drug_class":"Long-acting beta2-adrenergic agonist (LABA)","quality_score":null,"revenue":null,"mechanism":"Salmeterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle to improve airflow."},{"drug_id":"hydroxy-urea","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxy Urea","company_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite","quality_score":null,"revenue":null,"mechanism":"Hydroxyurea inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells."},{"drug_id":"hydroxy-urea","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxy Urea","company_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite","quality_score":null,"revenue":null,"mechanism":"Hydroxyurea inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells."},{"drug_id":"salmeterol-50-mcg-via-diskus","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salmeterol 50 mcg via DISKUS","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Beta2-adrenergic receptors","drug_class":"Long-acting beta2-adrenergic agonist (LABA)","quality_score":null,"revenue":null,"mechanism":"Salmeterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle to improve airflow."},{"drug_id":"oxybutynin-immediate-release","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oxybutynin immediate release","company_name":"Astellas Pharma Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors (M2 and M3)","drug_class":"Anticholinergic","quality_score":null,"revenue":null,"mechanism":"Oxybutynin is an anticholinergic that blocks muscarinic receptors in the bladder, leading to relaxation of the detrusor muscle and increased bladder capacity."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"dexketoprofen-trometamol-pethidine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"dexketoprofen trometamol + pethidine hydrochloride","company_name":"Kavaklıdere Umut Hospital","drug_phase":"marketed","molecular_target":"[\"cyclooxygenase (COX) enzymes\", \"mu-opioid receptors\"]","drug_class":"[\"NSAID\", \"opioid analgesic\"]","quality_score":null,"revenue":null,"mechanism":"Dexketoprofen trometamol and pethidine hydrochloride work together to provide potent analgesia by reducing inflammation and acting on opioid receptors in the central nervous system."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"levofloxacin-ophthalmic","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Levofloxacin Ophthalmic","company_name":"National University of Malaysia","drug_phase":"marketed","molecular_target":"DNA gyrase","drug_class":"Fluoroquinolone","quality_score":null,"revenue":null,"mechanism":"Levofloxacin ophthalmic is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, leading to bacterial cell death."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"chlortetracycline-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTETRACYCLINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"30S ribosomal subunit","drug_class":"Tetracycline","quality_score":0,"revenue":null,"mechanism":"Chlortetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome."},{"drug_id":"menveo-menactra","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Menveo®/Menactra®","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Neisseria meningitidis serogroups A, C, W, and Y","drug_class":"Conjugate vaccine","quality_score":0,"revenue":null,"mechanism":"Menveo® and Menactra® are conjugate vaccines that stimulate the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y."},{"drug_id":"riamet-artemether-lumefantrin-combination","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIAMET (artemether + LUMEFANTRIN combination)","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"marketed","molecular_target":"Plasmodium falciparum","drug_class":"Antimalarial","quality_score":0,"revenue":null,"mechanism":"Riamet combines artemether, a fast-acting antimalarial, with lumefantrine, a longer-acting partner, to provide a synergistic effect against Plasmodium falciparum."},{"drug_id":"danicopan","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DANICOPAN","company_name":"","drug_phase":"marketed","molecular_target":"Complement Factor D","drug_class":"Complement Factor D Inhibitor","quality_score":null,"revenue":null,"mechanism":"Danicopan is a selective inhibitor of complement Factor D, preventing the cleavage of Factor B and the formation of the C3 convertase in the alternative complement pathway."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"0-33-ropivacaine-250ml","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0.33% ropivacaine 250ml","company_name":"Guangzhou General Hospital of Guangzhou Military Command","drug_phase":"marketed","molecular_target":"Voltage-gated sodium channels","drug_class":"Local anesthetic","quality_score":51,"revenue":null,"mechanism":"Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses."},{"drug_id":"0-33-ropivacaine-250ml","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0.33% ropivacaine 250ml","company_name":"Guangzhou General Hospital of Guangzhou Military Command","drug_phase":"marketed","molecular_target":"Voltage-gated sodium channels","drug_class":"Local anesthetic","quality_score":51,"revenue":null,"mechanism":"Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses."},{"drug_id":"nicardipine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"nicardipine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"experimental-active-i-reconstruction-therapy","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Experimental: Active \"I-Reconstruction\" Therapy","company_name":"International Association Psychosomatics And Health Therapy","drug_phase":"marketed","molecular_target":"DNA gyrase and topoisomerase IV","drug_class":"Fluoroquinolone","quality_score":51,"revenue":null,"mechanism":"Ofloxacin ophthalmic solution is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"flumist-quadrivalent-2017-2018","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FluMist Quadrivalent (2017-2018)","company_name":"MedImmune LLC","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Live attenuated influenza vaccine (LAIV)","quality_score":49,"revenue":null,"mechanism":"FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection."},{"drug_id":"lidocaine-patch-local-application","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocaine patch local application","company_name":"Taipei Medical University Hospital","drug_phase":"marketed","molecular_target":"Sodium channels","drug_class":"Local anesthetic","quality_score":42,"revenue":null,"mechanism":"Lidocaine patch works by locally blocking sodium channels in nerve cells, which reduces the transmission of pain signals."},{"drug_id":"lamiduvine-epivir","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lamiduvine (Epivir)","company_name":"Catholic University of the Sacred Heart","drug_phase":"marketed","molecular_target":"HIV reverse transcriptase","drug_class":"Nucleoside Reverse Transcriptase Inhibitor (NRTI)","quality_score":51,"revenue":null,"mechanism":"Lamiduvine inhibits the HIV reverse transcriptase enzyme, preventing viral RNA from being converted into DNA, thus halting viral replication."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"captopril-test-dose-and-trandolapril","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Captopril Test Dose and Trandolapril","company_name":"Rigshospitalet, Denmark","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme (ACE)","drug_class":"Angiotensin-converting enzyme (ACE) inhibitors","quality_score":55,"revenue":null,"mechanism":"Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure."},{"drug_id":"captopril-test-dose-and-trandolapril","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Captopril Test Dose and Trandolapril","company_name":"Rigshospitalet, Denmark","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme (ACE)","drug_class":"Angiotensin-converting enzyme (ACE) inhibitors","quality_score":55,"revenue":null,"mechanism":"Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure."},{"drug_id":"bidil-xr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BiDil XR","company_name":"Arbor Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Vasculature and cardiac function","drug_class":"Vasodilators","quality_score":51,"revenue":null,"mechanism":"BiDil XR combines isosorbide dinitrate and hydralazine to enhance vasodilation and reduce cardiac workload, specifically benefiting patients with heart failure."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"attenuated-hepatitis-a-vaccine-h2-strain","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Attenuated Hepatitis A Vaccine, H2 Strain","company_name":"Jiangsu Province Centers for Disease Control and Prevention","drug_phase":"marketed","molecular_target":"Hepatitis A virus","drug_class":"Live attenuated vaccine","quality_score":46,"revenue":null,"mechanism":"The Attenuated Hepatitis A Vaccine, H2 Strain, works by introducing a live, weakened form of the hepatitis A virus to stimulate an immune response."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"montelukast-high-feno-group","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Montelukast (High FeNO group)","company_name":"Hull University Teaching Hospitals NHS Trust","drug_phase":"marketed","molecular_target":"CysLT1 receptor","drug_class":"Leukotriene receptor antagonist","quality_score":55,"revenue":null,"mechanism":"Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction."},{"drug_id":"montelukast-high-feno-group","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Montelukast (High FeNO group)","company_name":"Hull University Teaching Hospitals NHS Trust","drug_phase":"marketed","molecular_target":"CysLT1 receptor","drug_class":"Leukotriene receptor antagonist","quality_score":55,"revenue":null,"mechanism":"Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction."},{"drug_id":"actos-pioglitazone","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Actos (Pioglitazone)","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"PPAR-γ","drug_class":"Thiazolidinediones","quality_score":52,"revenue":null,"mechanism":"Actos (pioglitazone) is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues, particularly in adipose tissue, skeletal muscle, and liver."},{"drug_id":"flunarizine-and-or-pregabalin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"flunarizine and/or pregabalin","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"[\"L-type calcium channels\", \"alpha2-delta subunit of voltage-gated calcium channels\"]","drug_class":"[\"Calcium Channel Blocker\", \"Anticonvulsant\"]","quality_score":51,"revenue":null,"mechanism":"Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters."},{"drug_id":"flunarizine-and-or-pregabalin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"flunarizine and/or pregabalin","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"[\"L-type calcium channels\", \"alpha2-delta subunit of voltage-gated calcium channels\"]","drug_class":"[\"Calcium Channel Blocker\", \"Anticonvulsant\"]","quality_score":51,"revenue":null,"mechanism":"Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters."},{"drug_id":"fluticasone-propionate-hydrofluoroalkane-hfa","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"fluticasone propionate hydrofluoroalkane (HFA)","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Inhaled corticosteroid","quality_score":10,"revenue":null,"mechanism":"Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors."},{"drug_id":"fluticasone-propionate-hydrofluoroalkane-hfa","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"fluticasone propionate hydrofluoroalkane (HFA)","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Inhaled corticosteroid","quality_score":10,"revenue":null,"mechanism":"Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors."},{"drug_id":"tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis","company_name":"Sanofi Pasteur, a Sanofi Company","drug_phase":"marketed","molecular_target":"The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins.","drug_class":"Vaccine","quality_score":49,"revenue":null,"mechanism":"The Tdap vaccine works by introducing inactivated toxins from the bacteria that cause tetanus, diphtheria, and pertussis, stimulating the immune system to produce antibodies against these pathogens."},{"drug_id":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","company_name":"Orion Corporation, Orion Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors and β2-adrenergic receptors","drug_class":"Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)","quality_score":49,"revenue":null,"mechanism":"Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways."},{"drug_id":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","company_name":"Orion Corporation, Orion Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors and β2-adrenergic receptors","drug_class":"Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)","quality_score":49,"revenue":null,"mechanism":"Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways."},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":10,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."}],"pipeline":[{"drug_id":"venetoclax-rituximab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"naabak-eyedrops","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NAABAK eyedrops","company_name":"Laboratoires Thea","drug_phase":"marketed","molecular_target":"Ocular inflammation and discomfort","drug_class":"Ophthalmic solution","quality_score":8,"revenue":null,"mechanism":""},{"drug_id":"pregabalin-25-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pregabalin 25 MG","company_name":"Ajou University School of Medicine","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-gated calcium channels","drug_class":"Anticonvulsant","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pregabalin-25-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pregabalin 25 MG","company_name":"Ajou University School of Medicine","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-gated calcium channels","drug_class":"Anticonvulsant","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mdv3100","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MDV3100","generic_name":"mdv3100","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen","drug_class":"Androgen receptor inhibitor","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"alpha-blocker-monotherapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alpha blocker monotherapy","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"alpha-1 adrenergic receptors","drug_class":"Alpha blocker","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"alpha-blocker-monotherapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alpha blocker monotherapy","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"alpha-1 adrenergic receptors","drug_class":"Alpha blocker","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"ngenla-somatrogon","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08052666","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08052666","generic_name":"pf-08052666","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08052666","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08052666","generic_name":"pf-08052666","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cessation-phase-nicotine-patch-nicotine-mini-lozenge","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge","company_name":"University of Wisconsin, Madison","drug_phase":"marketed","molecular_target":"Nicotinic acetylcholine receptors","drug_class":"Nicotine replacement therapy (NRT)","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"losartan-amlodpine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"losartan/amlodpine","company_name":"University of Pavia","drug_phase":"marketed","molecular_target":"Angiotensin II receptors (AT1) and L-type calcium channels","drug_class":"Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ketamine-perfusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine perfusion","company_name":"University Tunis El Manar","drug_phase":"marketed","molecular_target":"NMDA receptor","drug_class":"Dissociative anesthetic","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ketamine-perfusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine perfusion","company_name":"University Tunis El Manar","drug_phase":"marketed","molecular_target":"NMDA receptor","drug_class":"Dissociative anesthetic","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"thyrogen","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thyrogen","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"Thyrotropin receptor","drug_class":"Recombinant human thyrotropin","quality_score":0,"revenue":null,"mechanism":"Thyrogen is a recombinant human thyrotropin that stimulates thyroid cells to produce and release thyroid hormones, aiding in the diagnosis and treatment of thyroid cancer."},{"drug_id":"pf-06939999-in-combination-with-docetaxel","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 in combination with docetaxel","generic_name":"pf-06939999-in-combination-with-docetaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein kinase","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pitavastin-4mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pitavastin 4mg","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"Statins","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"pitavastin-4mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pitavastin 4mg","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"Statins","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"ga-68-dotatoc","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ga-68-DOTATOC","company_name":"Weill Medical College of Cornell University","drug_phase":"marketed","molecular_target":"Somatostatin receptors (SSTRs) on neuroendocrine tumor cells","drug_class":"Radiopharmaceutical","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"insulin-injections","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Insulin injections","company_name":"University of Campania Luigi Vanvitelli","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"twinrix-for-atn-025","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Twinrix for ATN 025","company_name":"University of North Carolina, Chapel Hill","drug_phase":"marketed","molecular_target":"Hepatitis A virus and Hepatitis B virus","drug_class":"Vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anti-vegf-drug","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti-VEGF drug","company_name":"Xiaodong Sun","drug_phase":"marketed","molecular_target":"VEGF-A","drug_class":"Anti-VEGF","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anti-vegf-drug","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti-VEGF drug","company_name":"Xiaodong Sun","drug_phase":"marketed","molecular_target":"VEGF-A","drug_class":"Anti-VEGF","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"veklury","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Veklury","company_name":"ANRS, Emerging Infectious Diseases","drug_phase":"marketed","molecular_target":"NS5, Replicase polyprotein 1ab","drug_class":"Nucleoside analog prodrug","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"raltegravir-use-ral-as-a-simplification-strategy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raltegravir (Use RAL as a simplification strategy)","company_name":"Hospital Carlos III, Madrid","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","drug_class":"Integrase inhibitors","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"amnio-maxx-dual-layer-amnion-patch","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amnio-Maxx® Dual Layer Amnion Patch","company_name":"Royal Biologics","drug_phase":"marketed","molecular_target":"Wound healing and tissue regeneration","drug_class":"Biologic tissue graft","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"amnio-maxx-dual-layer-amnion-patch","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amnio-Maxx® Dual Layer Amnion Patch","company_name":"Royal Biologics","drug_phase":"marketed","molecular_target":"Wound healing and tissue regeneration","drug_class":"Biologic tissue graft","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"blinded-clopidogrel","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Blinded clopidogrel","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"P2Y12 receptor","drug_class":"Antiplatelet agents","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"recombinant-b-type-natriuretic-peptide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"recombinant B-type, natriuretic peptide","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Natriuretic peptide receptor-A (NPR-A)","drug_class":"Natriuretic peptides","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"recombinant-b-type-natriuretic-peptide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"recombinant B-type, natriuretic peptide","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Natriuretic peptide receptor-A (NPR-A)","drug_class":"Natriuretic peptides","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-07853578","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07853578","generic_name":"pf-07853578","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific protein]","drug_class":"Small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07853578","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07853578","generic_name":"pf-07853578","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific protein]","drug_class":"Small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"intravenous-ketamine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravenous Ketamine","company_name":"Rebecca Price","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"intravenous-ketamine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravenous Ketamine","company_name":"Rebecca Price","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"oral-viscous-budesonide-ovb","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral Viscous Budesonide (OVB)","company_name":"Azienda Policlinico Umberto I","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin-hydrochloride","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liposomal doxorubicin hydrochloride","company_name":"Cephalon, Inc.","drug_phase":"marketed","molecular_target":"DNA and topoisomerase II","drug_class":"Antineoplastic agent","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin-hydrochloride","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liposomal doxorubicin hydrochloride","company_name":"Cephalon, Inc.","drug_phase":"marketed","molecular_target":"DNA and topoisomerase II","drug_class":"Antineoplastic agent","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotropin-alpha","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chorionic Gonadotropin, Alpha","company_name":"Copenhagen University Hospital at Herlev","drug_phase":"marketed","molecular_target":"LH/CG receptor","drug_class":"Gonadotropins","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotropin-alpha","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chorionic Gonadotropin, Alpha","company_name":"Copenhagen University Hospital at Herlev","drug_phase":"marketed","molecular_target":"LH/CG receptor","drug_class":"Gonadotropins","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"intracanalicular-dexamethasone-0-4-mg-insert","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intracanalicular Dexamethasone, 0.4 mg insert","company_name":"Wolstan and Goldberg Eye Associates","drug_phase":"marketed","molecular_target":"Inflammatory mediators and immune cells in the ocular tissues","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"intracanalicular-dexamethasone-0-4-mg-insert","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intracanalicular Dexamethasone, 0.4 mg insert","company_name":"Wolstan and Goldberg Eye Associates","drug_phase":"marketed","molecular_target":"Inflammatory mediators and immune cells in the ocular tissues","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"test-formulation-treatment-a","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"elrantamab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrantamab","generic_name":"elrantamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen)","drug_class":"Bispecific Antibody","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07220060","generic_name":"pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07220060","generic_name":"pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"pf-07248144","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07248144","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"omega-3-acid-4-grams-per-day","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omega-3 acid 4 grams per day","company_name":"Inje University","drug_phase":"marketed","molecular_target":"Triglyceride synthesis, platelet aggregation, inflammatory pathways","drug_class":"Dietary supplement","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"omega-3-acid-4-grams-per-day","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omega-3 acid 4 grams per day","company_name":"Inje University","drug_phase":"marketed","molecular_target":"Triglyceride synthesis, platelet aggregation, inflammatory pathways","drug_class":"Dietary supplement","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"pf-08046045","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08046045","generic_name":"pf-08046045","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-08046045","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08046045","generic_name":"pf-08046045","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"oral-mini-pulse","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oral mini pulse","company_name":"Cairo University","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"oral-mini-pulse","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oral mini pulse","company_name":"Cairo University","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"donepezil-aricept","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"donepezil-aricept","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07293893","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07293893","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-07921585","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07921585","generic_name":"pf-07921585","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"gatifloxacin-0-3","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gatifloxacin 0.3%","company_name":"Innovative Medical","drug_phase":"marketed","molecular_target":"DNA gyrase and topoisomerase IV","drug_class":"Fluoroquinolone","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"loteprednol-and-tobramycin","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Loteprednol and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"Inflammatory mediators and bacterial protein synthesis","drug_class":"Corticosteroid/aminoglycoside combination","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"other-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Other treatment","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"other-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Other treatment","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tdf-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TDF treatment","company_name":"New Discovery LLC","drug_phase":"marketed","molecular_target":"Viral reverse transcriptase","drug_class":"Nucleotide reverse transcriptase inhibitor (NtRTI)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tdf-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TDF treatment","company_name":"New Discovery LLC","drug_phase":"marketed","molecular_target":"Viral reverse transcriptase","drug_class":"Nucleotide reverse transcriptase inhibitor (NtRTI)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"intranasal-glugagon","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intranasal glugagon","company_name":"A.O.U. Città della Salute e della Scienza","drug_phase":"marketed","molecular_target":"Liver","drug_class":"Hormonal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imotun","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imotun","company_name":"Chong Kun Dang Pharmaceutical","drug_phase":"marketed","molecular_target":"Specific signaling molecules","drug_class":"Biological modulator","quality_score":8,"revenue":null,"mechanism":""},{"drug_id":"linoladiol-estradiol","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linoladiol Estradiol","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Estrogen receptors (ERα and ERβ)","drug_class":"Synthetic estrogen","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"linoladiol-estradiol","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linoladiol Estradiol","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Estrogen receptors (ERα and ERβ)","drug_class":"Synthetic estrogen","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"fluticasone-furoate-umeclidinium-vilanterol-fuv","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)","company_name":"Thammasat University","drug_phase":"marketed","molecular_target":"Airway inflammation and bronchoconstriction","drug_class":"Combination inhaler (ICS/LAMA/LABA)","quality_score":30,"revenue":null,"mechanism":"FUV is a triple-combination inhaler that integrates a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to provide synergistic bronchodilation and anti-inflammatory effects."},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"0-09-bromfenac","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0,09% Bromfenac","company_name":"Hospital de La Luz","drug_phase":"marketed","molecular_target":"Cyclooxygenase-2 (COX-2)","drug_class":"Nonsteroidal Anti-Inflammatory Drug (NSAID)","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"ephedrine-continuous-infusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ephedrine, continuous infusion","company_name":"University of Parma","drug_phase":"marketed","molecular_target":"Alpha and beta-adrenergic receptors","drug_class":"Sympathomimetic amine","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ephedrine-continuous-infusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ephedrine, continuous infusion","company_name":"University of Parma","drug_phase":"marketed","molecular_target":"Alpha and beta-adrenergic receptors","drug_class":"Sympathomimetic amine","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ketamine-0-5mg-kg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine 0.5mg/kg","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"ketamine-0-5mg-kg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine 0.5mg/kg","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"naabak-eyedrops","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NAABAK eyedrops","company_name":"Laboratoires Thea","drug_phase":"marketed","molecular_target":"Ocular inflammation and discomfort","drug_class":"Ophthalmic solution","quality_score":8,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":87,"totalPipeline":137},"trials":{"data":[{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04475640","title":"Cancer Genetic Testing in Ethnic Populations","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01274338","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1673,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06176625","title":"Sight and Hearing Investigation Into Effects on Delirium","phase":"","overall_status":"COMPLETED","enrollment_count":1543,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06310486","title":"The Emergency Call on Drowning","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT03301493","title":"Genomic Testing and Resulting Medical Decisions","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT06334276","title":"Developing an Utstein-style Danish Drowning Registry: Nationwide Fatal and Nonfatal Drowning Data Since 2016","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT04738370","title":"Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06310499","title":"Primary or Secondary Drowning","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT03199209","title":"Your Health Matters! (Tu Salud ¡Si Cuenta!): Promoting Healthy Lifestyles in Latino Families","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03498521","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07454161","title":"Bleeding Disorder of Unknown Cause in the Netherlands","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03010150","title":"Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":471,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07283939","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03441321","title":"Social-Media Intervention in Reducing Tanning in High-Risk Tanners","phase":"NA","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Jerod L Stapleton, PhD","has_results":true},{"nct_id":"NCT00588770","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":403,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06312202","title":"Drowning Incidents in Danish Harbours","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT02194387","title":"Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02780427","title":"ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT03234556","title":"Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07430475","title":"Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"University of Adelaide","has_results":false},{"nct_id":"NCT07007832","title":"Bile Omics for Diagnosing Indeterminate Biliary Strictures","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06322134","title":"Drowning Incidents Treated by the Danish SAR Helicopters","phase":"","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Prehospital Center, Region Zealand","has_results":false},{"nct_id":"NCT05723185","title":"Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":246,"lead_sponsor_name":"Rovere Querini Patrizia","has_results":false},{"nct_id":"NCT01540058","title":"Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":243,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT04456140","title":"Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04952103","title":"Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03258554","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT03278600","title":"Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03674229","title":"Patients Navigators in Facilitating Weight Management in Obese Participants","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":171,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02941315","title":"Risk Stratification of Heart Failure in Cardiomyopathies.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04739956","title":"Psychological Impact of Pregnancy of Unknown Location","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT05263700","title":"FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Peter MacCallum Cancer Centre, Australia","has_results":false},{"nct_id":"NCT05918510","title":"Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","phase":"","overall_status":"RECRUITING","enrollment_count":142,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT07535554","title":"The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06140992","title":"PaCIFiC-CUP Classifies Cancer of Unknown Primary","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07372963","title":"18F-FAPI PET in Cancers of Unknown Primary Site","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT05576974","title":"A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04750109","title":"Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT03725449","title":"Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05046444","title":"Solving Riddles Through Sequencing","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Munich Leukemia Laboratory","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}